E4412; A Phase 1 Study with an Expansion Cohort of the Combination of Ipilimumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: Hodgkin Lymphoma
Age: Between 18 - 100 Years
Gender: Male or Female
Must have pathologically confirmed relapsed or refractory classical Hodgkins Lymphoma
Must have relapsed after first line chemotherapy
Women must not be pregnant or breast-feeding
Evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 92% while breathing room air
Evidence of prior malignancy
Have autoimmune disorders or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required